Medication info
Cozartan Plus F Tablets

Cozartan Plus F Tablets

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›100mg / 1 tabletHydrochlorothiazide›25mg / 1 tablet
Manufacturer / importer
Dong-A ST Co., Ltd.
Appearance
Light yellow oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 200805918 · Notified 2008.05.27 · Insurance code 642505210

Summary

Main use
Treatment of hypertension not controlled by monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the expected effect is not achieved with monotherapy. 1. Replacement therapy : The combination therapy of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy : Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy : Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia even when their blood pressure is controlled with this dose : Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without decreasing the overall blood pressure-lowering effect. Subsequently, monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg continuously. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or higher. Use of loop diuretics rather than thiazide drugs is preferable in patients with more severe renal impairment; therefore, administration to these patients is not recommended. ○ Patients with hepatic impairment Because this medicine cannot provide the initial dose of losartan potassium 25 mg for patients with hepatic impairment requiring dose adjustment, its use in these patients is not recommended.
Child dose
Pediatric patients (under 18 years) Since there is no experience with its use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to pediatric patients or adolescents.

Ingredients

Manufacturer
Dong-A ST Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled by monotherapy

  • Hypertension
View approved original text

This medication is used for hypertension that is not adequately controlled with monotherapy.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the expected effect is not achieved with monotherapy. 1. Replacement therapy : The combination therapy of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy : Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy : Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia even when their blood pressure is controlled with this dose : Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without decreasing the overall blood pressure-lowering effect. Subsequently, monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg continuously. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or higher. Use of loop diuretics rather than thiazide drugs is preferable in patients with more severe renal impairment; therefore, administration to these patients is not recommended. ○ Patients with hepatic impairment Because this medicine cannot provide the initial dose of losartan potassium 25 mg for patients with hepatic impairment requiring dose adjustment, its use in these patients is not recommended.

Child dose

Pediatric patients (under 18 years) Since there is no experience with its use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to pediatric patients or adolescents.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. This medication should not be administered to patients with certain allergic reactions or significantly decreased renal function, or severe hepatic impairment. Caution should be exercised when using this medication in patients with very low blood pressure, electrolyte imbalances, hyperuricemia, or gout, as well as in elderly patients. This medication can affect serum potassium levels, so potassium supplements or potassium-containing medications should not be taken arbitrarily, and electrolyte levels should be regularly checked through blood tests. This medication contains hydrochlorothiazide, which can make the skin more sensitive to sunlight, so sun exposure should be limited, and if any skin abnormalities occur, a doctor should be consulted immediately. Dizziness or drowsiness may occur while taking this medication, so caution is needed when driving or operating dangerous machinery. This medication can affect kidney function, so patients with impaired kidney function require regular testing, and if any adverse symptoms appear during medication use, immediate consultation with medical personnel is necessary. Safety has not been established for children and adolescents, so it is not administered to this age group. When taking this medication, the exact dosage and administration instructions provided by the doctor should be followed, and it should not be stopped or the dosage changed arbitrarily.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • lumbago
  • dizziness
Show 128 more
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
  • skin shedding phenomenon
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • myocardial infarction
  • second-degree atrioventricular block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • indigestion
  • flatulence
  • gastritis
  • vomiting
  • malaise
  • anemia
  • gout
  • arm pain
  • arthralgia
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • nervous hypersensitivity
  • panic disorder
  • sensory abnormality
  • peripheral neuropathy
  • sleep disturbance
  • drowsiness
  • tremor
  • shortness of breath
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • purpura
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • visual impairment
  • taste disturbance
  • tinnitus
  • erectile dysfunction
  • nocturnal enuresis
  • polyuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsion
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle spasm
  • restlessness
  • renal failure
  • renal dysfunction
  • interstitial nephritis
  • Stevens-Johnson syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute angle-closure glaucoma
  • choroidal exudate
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythematous skin syndrome
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a container that blocks light. Additionally, it is recommended to store the medication at room temperature between 1 and 30 degrees Celsius. Storing the medication in this manner helps maintain its effectiveness and safety.

Appearance and packaging

Appearance

Light yellow oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.